drugset / Trial / NCT03628066
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study will look at the safety and effectiveness of the combination of palbociclib and letrozole and ovarian suppression for premenopausal patients who have ER-positive/HER2-negative breast cancer that has not yet been treated.
Timeline
- Start
- 2018-10-22
- Primary completion
- 2020-11-30
- Completion
- 2021-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Goserelin | Other / unclassified | 3.6 mg | Subcutaneous |
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |
| Subject | Palbociclib | Small molecule | 125 mg | Oral |